Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | ACACB | O00763 | 1/20 | 0.46 |
| ▸ | ACACA | Q13085 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16491286 | 1.00 | AAK1 (0.50) | AAK1MAPTMTNR1AMTNR1BALDH1A1 | |
| SCHEMBL27895372 | 0.87 | MTNR1A (0.49) | MTNR1AMTNR1BCTSSCTSKACACB | |
| SCHEMBL21529047 | 0.86 | CA1 (0.51) | AAK1MAPTALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL21529048 | 0.86 | CA1 (0.51) | AAK1MAPTALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL18290032 | 0.86 | MTNR1A (0.48) | MTNR1AMTNR1BACACBACACA | |
| SCHEMBL18027261 | 0.86 | MTNR1A (0.48) | MTNR1AMTNR1BACACBACACA | |
| SCHEMBL507002 | 0.86 | MTNR1A (0.66) | MTNR1AMTNR1BCTSSCTSK | |
| SCHEMBL507001 | 0.86 | MTNR1A (0.66) | MTNR1AMTNR1BCTSSCTSK | |
| SCHEMBL30241501 | 0.86 | MTNR1A (0.66) | MTNR1AMTNR1BCTSSCTSK | |
| SCHEMBL16491290 | 0.85 | MAPT (0.48) | AAK1MAPTALDH1A1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326756-A1 | METHOD FOR PRODUCING 3,6-DISUBSTITUTED-IMIDAZO[1,2-B]PYRIDAZINE COMPOUNDS | NUVATION BIO INC (US) | 2025-10-23 | — | — | US | disclosed |
| WO-2023220967-A1 | METHOD FOR PRODUCING 3,6-DISUBSTITUTED-IMIDAZO[1,2-B]PYRIDAZINE COMPOUNDS | ANHEART THERAPEUTICS (HANGZHOU) CO., LTD. (CN) | 2023-11-23 | — | — | WO | disclosed |
| US-20230227459-A1 | METHOD FOR PRODUCING 3,6-DISUBSTITUTED-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-07-20 | — | — | US | disclosed |
| US-20230227459-A1 | METHOD FOR PRODUCING 3,6-DISUBSTITUTED-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-07-20 | — | — | US | disclosed |
| US-20230227459-A1 | METHOD FOR PRODUCING 3,6-DISUBSTITUTED-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-07-20 | — | — | US | disclosed |
| EP-3597648-B1 | METHOD FOR PRODUCING 3, 6-DISUBSTITUTED IMIDAZO[1, 2-b]PYRIDAZINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2023-06-07 | — | — | EP | disclosed |
| US-11667642-B2 | Method for producing 3,6-disubstituted-imidazo[1,2-b]pyridazine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-06-06 | — | — | US | disclosed |
| US-11667642-B2 | Method for producing 3,6-disubstituted-imidazo[1,2-b]pyridazine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-06-06 | — | — | US | disclosed |
| US-11667642-B2 | Method for producing 3,6-disubstituted-imidazo[1,2-b]pyridazine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-06-06 | — | — | US | disclosed |
| EP-4101853-A1 | METHOD FOR PRODUCING 3,6-DISUBSTITUTED-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2022-12-14 | — | — | EP | disclosed |
| US-9394301-B2 | [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-07-19 | — | — | US | disclosed |
| US-20150246915-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-09-03 | — | — | US | disclosed |
| US-9012633-B2 | [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-04-21 | — | — | US | disclosed |
| EP-2217578-B9 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE COMPOUNDS AND THEIR USE | CANCER REC TECH LTD (GB) | 2014-09-10 | — | — | EP | disclosed |
| US-20140155594-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-06-05 | — | — | US | disclosed |
| US-8431596-B2 | [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-04-30 | — | — | US | disclosed |
| US-8431596-B2 | [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-04-30 | — | — | US | disclosed |
| US-20100298339-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
| US-20100298339-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
| WO-2009047514-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227459-A1 | METHOD FOR PRODUCING 3,6-DISUBSTITUTED-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVE | ADIPOR1, ADIPOR2, FABP4 | AAK1 991/4885MAPT 3588/4885MTNR1A 440/4885 |
| US-20150246915-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | AXL, TYRO3, FLT3 | AAK1 231/4885MAPT 2221/4885MTNR1A 1009/4885 |
| US-20250326756-A1 | METHOD FOR PRODUCING 3,6-DISUBSTITUTED-IMIDAZO[1,2-B]PYRIDAZINE COMPOUNDS | NISCH, CYP4B1, CYP2W1 | AAK1 1744/4885MAPT 2160/4885MTNR1A 2088/4885 |
| US-20100298339-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | AXL, TYRO3, FLT3 | AAK1 231/4885MAPT 2221/4885MTNR1A 1009/4885 |
| US-20140155594-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | AXL, TYRO3, FLT3 | AAK1 231/4885MAPT 2221/4885MTNR1A 1009/4885 |
| US-11667642-B2 | Method for producing 3,6-disubstituted-imidazo[1,2-b]pyridazine derivative | CBR3, DHPS, HRH4 | AAK1 1358/4885MAPT 4242/4885MTNR1A 3094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.